Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXTEND-AGNES TNK
NCT05892510Phase 3Recruiting
- Sponsor
- University of Melbourne
- Start
- Jun 2024
- Primary completion
- Aug 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Placebo with Intra-arterial tenecteplase (2 arms). Primary endpoints: Early Neurological Improvement and Functional independence at 3 months. Started Jun 2024; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05892510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05892510.